Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections

Clin Infect Dis. 2021 Oct 5;73(7):e1754-e1757. doi: 10.1093/cid/ciaa1847.


Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurred after 11 of 12 treatment courses. However, microbiologic relapse was observed after 11 of 12 treatment courses, notably without emergence of resistance.

Keywords: Achromobacter xylosoxidans; cefiderocol; cystic fibrosis; lung transplantation; pneumonia.

MeSH terms

  • Achromobacter denitrificans*
  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Cefiderocol
  • Cephalosporins
  • Child
  • Cystic Fibrosis* / complications
  • Cystic Fibrosis* / drug therapy
  • Gram-Negative Bacterial Infections* / drug therapy
  • Humans


  • Anti-Bacterial Agents
  • Cephalosporins